


PHARMACEUTICAL 2021



Akebia Therapeutics Inc. Rank 280 of 409





PHARMACEUTICAL 2021

Akebia

Akebia Therapeutics Inc. Rank 280 of 409

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 205% points.

The company's Economic Capital Ratio, given in the ranking table, is -247%, being 108% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	371,437
Cost of Goods Sold	295,908
Intangible Assets	55,053
Liabilities, Current	187,146
Liabilities, Non-Current	206,955
Other Assets	209,027
Other Compr. Net Income	13
Other Expenses	3,409
Other Liabilities	2,420
Other Net Income	-7,015
Property and Equipment	8,622
Research and Development	218,485
Revenues	295,307
Selling, General and Administrative Expense	153,947

Output Variable	Value in 1000 USD
Assets	644,139
Liabilities	396,521
Expenses	671,749
Stockholders Equity	247,618
Net Income	-383,457
Comprehensive Net Income	-383,450
Economic Capital Ratio	-247%